OBJECTIVES: Buprenorphine is associated with enhanced human immunodeficiency virus (HIV) treatment outcomes including increased antiretroviral therapy initiation rates, adherence, and CD4 cell counts among HIV-infected opioid-dependent individuals. Buprenorphine facilitates hepatitis C virus (HCV) treatment in opioid-dependent patients with HCV monoinfection. Less is known about buprenorphine's role in HIV/HCV coinfection. METHODS: We conducted a retrospective chart review to evaluate HCV care for HIV-infected buprenorphine patients in the first 4 years of buprenorphine's integration into a Rhode Island HIV clinic. RESULTS: Sixty-one patients initiated buprenorphine. All had HCV antibody testing; 57 (93%) were antibody-positive. All antibody-positive patients underwent HCV RNA testing; 48 (84%) were RNA-positive. Of these, 15 (31%) were not referred to HCV care. Among chronically infected patients, 3 received HCV treatment after buprenorphine; all had cirrhosis and none achieved viral eradication. At buprenorphine induction, most patients had inadequately controlled HIV infection, with detectable HIV RNA (59%) or CD4 cell count less than or equal to 350/μL (38%). CONCLUSIONS: Buprenorphine has shown limited success to date as a bridge to HCV treatment within an HIV clinic. Buprenorphine's stabilization of opioid dependence and HIV disease may permit the use of HCV therapy over time.
OBJECTIVES:Buprenorphine is associated with enhanced human immunodeficiency virus (HIV) treatment outcomes including increased antiretroviral therapy initiation rates, adherence, and CD4 cell counts among HIV-infected opioid-dependent individuals. Buprenorphine facilitates hepatitis C virus (HCV) treatment in opioid-dependent patients with HCV monoinfection. Less is known about buprenorphine's role in HIV/HCV coinfection. METHODS: We conducted a retrospective chart review to evaluate HCV care for HIV-infectedbuprenorphinepatients in the first 4 years of buprenorphine's integration into a Rhode Island HIV clinic. RESULTS: Sixty-one patients initiated buprenorphine. All had HCV antibody testing; 57 (93%) were antibody-positive. All antibody-positive patients underwent HCV RNA testing; 48 (84%) were RNA-positive. Of these, 15 (31%) were not referred to HCV care. Among chronically infectedpatients, 3 received HCV treatment after buprenorphine; all had cirrhosis and none achieved viral eradication. At buprenorphine induction, most patients had inadequately controlled HIV infection, with detectable HIV RNA (59%) or CD4 cell count less than or equal to 350/μL (38%). CONCLUSIONS:Buprenorphine has shown limited success to date as a bridge to HCV treatment within an HIV clinic. Buprenorphine's stabilization of opioid dependence and HIV disease may permit the use of HCV therapy over time.
Authors: Elinore F McCance-Katz; David E Moody; Gene D Morse; Gerald Friedland; Patricia Pade; Jennifer Baker; Anika Alvanzo; Patrick Smith; Abayomi Ogundele; Peter Jatlow; Petrie M Rainey Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Elinore F McCance-Katz; David E Moody; Patrick F Smith; Gene D Morse; Gerald Friedland; Patricia Pade; Jennifer Baker; Anika Alvanzo; Peter Jatlow; Petrie M Rainey Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Juan A Pineda; José A García-García; Manuela Aguilar-Guisado; María J Ríos-Villegas; Josefa Ruiz-Morales; Antonio Rivero; José del Valle; Rafael Luque; Jesús Rodríguez-Baño; Mercedes González-Serrano; Angela Camacho; Juan Macías; Israel Grilo; Jesús M Gómez-Mateos Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: V de Lédinghen; P Barreiro; J Foucher; P Labarga; L Castéra; M E Vispo; P-H Bernard; L Martin-Carbonero; D Neau; P García-Gascó; W Merrouche; V Soriano Journal: J Viral Hepat Date: 2008-01-22 Impact factor: 3.728
Authors: Jason Grebely; Jesse D Raffa; Caite Meagher; Fiona Duncan; Krista A Genoway; Milan Khara; Mark McLean; Annabel Mead; Mark Viljoen; Stanley DeVlaming; Chris Fraser; Brian Conway Journal: J Gastroenterol Hepatol Date: 2007-07-20 Impact factor: 4.029
Authors: Lynn E Taylor; Julie A Foont; Allison K DeLong; Alysse Wurcel; Benjamin P Linas; Stacey Chapman; Michaela A Maynard; Susan Cu-Uvin; Kenneth H Mayer Journal: AIDS Patient Care STDS Date: 2014-01 Impact factor: 5.078
Authors: Kenneth Blum; Marlene Oscar-Berman; John Femino; Roger L Waite; Lisa Benya; John Giordano; Joan Borsten; William B Downs; Eric R Braverman; Raquel Loehmann; Kristina Dushaj; David Han; Thomas Simpatico; Mary Hauser; Debmalya Barh; Thomas McLaughlin Journal: J Addict Res Ther Date: 2013-04-23
Authors: Victoria Haldane; Francisco Cervero-Liceras; Fiona Lh Chuah; Suan Ee Ong; Georgina Murphy; Louise Sigfrid; Nicola Watt; Dina Balabanova; Sue Hogarth; Will Maimaris; Kent Buse; Peter Piot; Martin McKee; Pablo Perel; Helena Legido-Quigley Journal: J Int AIDS Soc Date: 2017-05-30 Impact factor: 5.396